Jack Schuler is an independent director of Accelerate Diagnostics, an in vitro diagnostics company providing lifesaving solutions for serious infections.
He also serves as a director for Biodesix, Inc. and Minute Molecular Diagnostics, Inc., and he has previously served on the boards of directors for Ventana Medical Systems, Medtronic, Stericycle, and Quidel Corporation.
Schuler has a career spanning 30 years in the pharmaceutical industry, including a variety of executive positions at Abbott Laboratories, most recently as president and chief operating officer. He is also a founding partner of private equity firm Crabtree Partners.
Additionally, he is the co-founder and chairman of The Schuler Scholar Program, which assists high-achieving and underrepresented students in gaining access to selective universities. Schuler founded the program in 2001 with his daughter, Natasha.
Schuler earned his B.S. in mechanical engineering from Tufts University and his M.B.A. from Stanford University’s Graduate School of Business Administration. He resides in Lake Bluff, Illinois with his wife, Renate.
What is Jack W. Schuler's net worth?
The estimated net worth of Jack W. Schuler is at least $116,214.42 as of December 19th, 2023. Mr. Schuler owns 65,289 shares of Accelerate Diagnostics stock worth more than $116,214 as of November 20th. This net worth evaluation does not reflect any other assets that Mr. Schuler may own. Learn More about Jack W. Schuler's net worth.
How do I contact Jack W. Schuler?
Has Jack W. Schuler been buying or selling shares of Accelerate Diagnostics?
Jack W. Schuler has not been actively trading shares of Accelerate Diagnostics during the last ninety days. Most recently, on Tuesday, January 18th, Jack W. Schuler bought 4,191 shares of Accelerate Diagnostics stock. The stock was acquired at an average cost of $39.40 per share, with a total value of $165,125.40. Learn More on Jack W. Schuler's trading history.
Who are Accelerate Diagnostics' active insiders?
Are insiders buying or selling shares of Accelerate Diagnostics?
During the last twelve months, insiders at the medical research company sold shares 11 times. They sold a total of 99,466 shares worth more than $87,222.72. The most recent insider tranaction occured on May, 20th when CTO Larry Michael Mertz sold 361 shares worth more than $317.68. Insiders at Accelerate Diagnostics own 43.6% of the company.
Learn More about insider trades at Accelerate Diagnostics. Information on this page was last updated on 5/20/2024.
